2024 IPO

Quote

anonymous

Guest
The fundamental issue Galderma will face post IPO is that the growth rates cannot be sustained long term. Here is why:

1. The aesthetic market is saturated right now especially in the US. Demand will soften as cost of living increases.
2. Reimbursement nightmare is just beginning for the Rx business and it will be a house of cards for Nemo.
3. The IPO will generate $$$ based on share price and volume, but only in the short run. Anyone remember what the initial price of Facebook was? What it dropped to within 30 days? Where it trades today? The initial pop will be nice for Galderma, but after 6 months, oncethe stock settles in at a low share price, all hell will break loose.
More layoffs and cost control measures will be in place in order to get someone to come buy the company.
 




























anonymous said:
The fundamental issue Galderma will face post IPO is that the growth rates cannot be sustained long term. Here is why:

1. The aesthetic market is saturated right now especially in the US. Demand will soften as cost of living increases.
2. Reimbursement nightmare is just beginning for the Rx business and it will be a house of cards for Nemo.
3. The IPO will generate $$$ based on share price and volume, but only in the short run. Anyone remember what the initial price of Facebook was? What it dropped to within 30 days? Where it trades today? The initial pop will be nice for Galderma, but after 6 months, oncethe stock settles in at a low share price, all hell will break loose.
More layoffs and cost control measures will be in place in order to get someone to come buy the company.
Click to expand...
Truths from this posts are:
  • Ax growth in US is weak
  • Negative Rx price impact
  • More layoffs coming
Don’t expect the situation to improve.
 




Zug, Switzerland – June 26, 2023 – Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The transaction is expected to close in the coming weeks. Galderma will use the proceeds of the private placement to strengthen its balance sheet and to further accelerate its organic growth momentum fueled by its unique integrated dermatology strategy.
 




anonymous said:
Zug, Switzerland – June 26, 2023 – Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The transaction is expected to close in the coming weeks. Galderma will use the proceeds of the private placement to strengthen its balance sheet and to further accelerate its organic growth momentum fueled by its unique integrated dermatology strategy.
Click to expand...
Of course no IPO and they keep promising. They need to get it ready to sell off.
 




anonymous said:
Zug, Switzerland – June 26, 2023 – Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The transaction is expected to close in the coming weeks. Galderma will use the proceeds of the private placement to strengthen its balance sheet and to further accelerate its organic growth momentum fueled by its unique integrated dermatology strategy.
Click to expand...
No mention of IPO. Because it‘s not happening.
 




anonymous said:
Zug, Switzerland – June 26, 2023 – Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The transaction is expected to close in the coming weeks. Galderma will use the proceeds of the private placement to strengthen its balance sheet and to further accelerate its organic growth momentum fueled by its unique integrated dermatology strategy.
Click to expand...
Another step closer to Galderma splitting up or being sold.
 




This sounds like the current investors put more money in Galderma to pay down debt and make the balance sheet look better. All of the original investors are probably worried of losing their initial investment dollars and this is a safety net to extend their hopes of recovery for another year. All these rich brilliant abu Dabi investment people would have been better off tossing their blood money in the stock market instead.
 




anonymous said:
This sounds like the current investors put more money in Galderma to pay down debt and make the balance sheet look better. All of the original investors are probably worried of losing their initial investment dollars and this is a safety net to extend their hopes of recovery for another year. All these rich brilliant abu Dabi investment people would have been better off tossing their blood money in the stock market instead.
Click to expand...
Great work Flemming! #Galdermaproud
 




anonymous said:
This sounds like the current investors put more money in Galderma to pay down debt and make the balance sheet look better. All of the original investors are probably worried of losing their initial investment dollars and this is a safety net to extend their hopes of recovery for another year. All these rich brilliant abu Dabi investment people would have been better off tossing their blood money in the stock market instead.
Click to expand...
Bingo! Playing roulette is a safer bet. After 3 failed IPO attempts, Galderma had to do something to mask the charade.
 




anonymous said:
Zug, Switzerland – June 26, 2023 – Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The transaction is expected to close in the coming weeks. Galderma will use the proceeds of the private placement to strengthen its balance sheet and to further accelerate its organic growth momentum fueled by its unique integrated dermatology strategy.
Click to expand...
IPO is wishful thinking. This is just a deterrent strategy before this company blows up leaving a financial disaster trail behind.
 




After a monster private placement there is virtually no chance of an IPO at this point. We were promised one to keep people from fleeing. An IPO would require extensive examination of management and finances, which it seems would not be welcomed. But we can at least pay big CEO salaries.
 




anonymous said:
After a monster private placement there is virtually no chance of an IPO at this point. We were promised one to keep people from fleeing. An IPO would require extensive examination of management and finances, which it seems would not be welcomed. But we can at least pay big CEO salaries.
Click to expand...
If this company was ever audited, many people would probably go to jail. This company is such a scam and will eventually be found out.
 




All these LinkedIn posts from the WCD are sickening. It’s an alibi to hide from the truth. Nothing good is happening at Galderma, so shoving daily non-events to the forefront is just an other excuse to pretend this company has any value.
 




anonymous said:
All these LinkedIn posts from the WCD are sickening. It’s an alibi to hide from the truth. Nothing good is happening at Galderma, so shoving daily non-events to the forefront is just an other excuse to pretend this company has any value.
Click to expand...
Remember LinkedIn is free and visible. An ideal platform to fool future investors while Flemming and EQT find an exit strategy.
 




Top Bottom
Back
Quote